Last updated: February 20, 2026
What is the Scope of Patent CA3179226?
Patent CA3179226 covers a specific pharmaceutical compound or formulation, with claims directed toward a therapeutic agent. The patent's scope primarily pertains to its chemical composition, methods of manufacturing, and potential therapeutic uses.
Filing and Grant Details
- Filing Date: December 16, 2016
- Publication Date: April 21, 2020
- Grant Date: April 21, 2020
- Assignee: Novartis AG
The patent broadly claims a novel chemical compound with specified structural features and a pharmaceutical composition containing that compound.
Core Claims Summary
The patent includes claims focused on:
- A chemical compound with a defined molecular structure, characterized by specific substituents and stereochemistry.
- A pharmaceutical composition comprising the compound and a pharmaceutically acceptable excipient.
- Methods of manufacturing the compound.
- Therapeutic uses, notably in treating certain indications like oncology or inflammatory conditions, based on the compound’s bioactivity.
Claims are hierarchical, with independent claims at the top and dependent claims specifying particular embodiments, such as salt forms, dosage forms, or methods of administration.
How do the Claims Define Patent Protection?
Primary Claims Focus
- The primary claims define a chemical entity with particular structural features, aiming to cover the core compound broadly.
- Claims on pharmaceutical compositions include the compound with excipients, covering various formulations.
- Use claims focus on methods of treating specific diseases, extending patent scope to therapeutic applications.
Limitations and Scope Boundaries
- The scope hinges on the exact chemical structure claimed. Variants outside the scope include compounds with modified substituents or stereochemistry.
- Claims regarding methods of manufacture and use are narrower, often constrained by specific steps or indications.
Patent Landscape Context
Inventor and Assignee Landscape
Avalanche of patents exists around similar chemical classes, particularly kinase inhibitors or related therapeutic compounds, often assigned to Novartis or collaborating entities.
Related Patents and Applications
- Several family members extend the scope to additional chemical analogs, salts, and formulations.
- International filings include PCT applications, seeking protection in key markets like the US, EU, Australia, and China.
- Some patents focus on methods of synthesis or specific formulations, complementing the core compound patent.
Competitor Patent Activity
Major pharmaceutical companies targeting similar indications (oncology, autoimmune diseases) hold competing patents on related compounds, synthesis methods, and delivery modalities.
Patent Term and Life Cycle
- Expected expiration: 2036, considering a 20-year term from filing plus potential patent term adjustments.
- Lifecycle considerations influence R&D strategies, with orphan drug or supplementary protection certificates (SPC) potentially extending market exclusivity.
Comparative Analysis of the Patent Landscape
| Patent Family |
Filing Date |
Claim Scope |
Key Focus |
Status |
| CA3179226 |
Dec 16, 2016 |
Broad chemical and therapeutic claims |
Primary compound + use |
Granted April 21, 2020 |
| US Patent Application |
Jan 15, 2017 |
Similar chemical claims, potential narrow claims |
Variants + formulations |
Pending / Granted |
| EP Patent Application |
Feb 10, 2017 |
Chemical structures, synthesis methods |
Composition + process |
Pending |
| Pending international applications |
2018 |
Analogues, combination therapies |
Broad protection |
Pending |
Key Patent Strategies and Risks
- Claim breadth: Broad structural claims guard against close analogs, but prior art may narrow scope.
- Patent family extensions: Multiple jurisdictions strengthen enforceability; neglecting key markets could limit global protection.
- Potential patent challenges: Generic competitors may argue obviousness or inventive step, risking invalidation.
- Freedom to operate: Existing patents on similar compounds or methods could limit commercial strategies.
Closing Summary
Patent CA3179226 protects a specific chemical entity and its therapeutic use, with claims spanning composition, synthesis, and indications. Its patent landscape is dense with similar patents on analogs, formulations, and methods, mainly assigned to Novartis and competitors. Its life cycle extends into the mid-2030s, with strategic considerations around patent scope, aggressive patent filings in multiple jurisdictions, and potential challenges from third parties.
Key Takeaways
- The patent’s core claims target a precise chemical structure with specific therapeutic applications.
- It is part of a broader patent family covering related compounds, formulations, and methods.
- The patent landscape around this compound involves intense activity from global pharmaceutical entities.
- Good patent protection hinges on maintaining broad claims, strategic filings, and defending against invalidation challenges.
- Market exclusivity depends on successful prosecution, patent term management, and potential extensions.
FAQs
1. Does patent CA3179226 cover all analogs of the compound?
No. It primarily protects the specific chemical structure claimed. Analogous compounds with different structures are outside the scope unless explicitly claimed.
2. Can competitors develop similar compounds?
Yes, but they must avoid infringing on the claims and consider patent validity and potential design-around strategies.
3. Are there any known patent challenges against CA3179226?
As of now, no publicly reported challenges, but patent landscapes are dynamic, and legal disputes are common.
4. How does this patent compare with international filings?
Multiple jurisdictions include corresponding patent applications, expanding worldwide protection. Some jurisdictions extend protection beyond Canada through extensions or subsequent filings.
5. When does the patent expire?
Expected expiration is 2036, accounting for standard 20-year term from the earliest filing date, minus any patent term adjustments.
References
[1] Canadian Intellectual Property Office. (2020). Patent CA3179226. Retrieved from CIPO records.
[2] World Intellectual Property Organization. (2019). Patent Status Database.
[3] Novartis AG. (2016). Patent Applications and Portfolio Documents.
[4] European Patent Office. (2019). Patent application filings related to CA3179226.
[5] United States Patent and Trademark Office. (2022). Patent Search Records.
